
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate Inc operates within a growing market, as total ADHD medication sales in the U.S. have increased by approximately 8% annually since 2010, reaching around $18 billion in 2020. The company has demonstrated promising results from the CTx-1301 clinical trials, with positive topline data indicating a favorable effect compared to placebo in subjects. These factors underscore the potential for substantial growth and highlight the company's capability to address unmet needs in ADHD treatment, contributing to a positive outlook for Cingulate's stock.
Bears say
Cingulate Inc reported a net loss of $4.8 million with an EPS of $(1.09), which exceeded negative estimates and consensus expectations for the quarter, reflecting challenges in financial performance. Additionally, the company faced a more significant net loss of $7.3 million in a subsequent period, underscoring ongoing operational difficulties and exceeded earlier estimations for losses. The analysis highlights critical risks including balance sheet and liquidity concerns, potential clinical trial failures, regulatory setbacks, and competitive pressures, collectively contributing to a negative outlook for the stock.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares